“The Immuno-Oncology Curve” with Dr. Steven O’Day – Guest is Alexander (Lex) Eggermont
Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn:
“I’m excited to announce that the first episode of my new podcast, “The Immuno-Oncology Curve,” is now available. In this inaugural episode, I had the privilege to speak with Alexander (Lex) Eggermont MD, PhD, one of the world’s pioneering immunotherapy experts.
Among other great insights, Lex talks about creating a “school” for the anti-cancer immune system – a powerful metaphor as we seek to understand and share the rising potential of next-generation immuno-oncology treatments.
I welcome your thoughts on this episode in the comments below!”
Episode 1: Sending the Immune System Back to School Against Cancer
Source: Steven O’Day / LinkedIn
Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Dr O’Day played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.
Alexander (Lex) Eggermont is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development. He currently holds roles as Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology, the Netherlands; Professor of Oncology (Classe Exceptionelle) at Paris-Saclay University, France; Coordinator, Comprehensive Cancer Center Program for Deutsche KrebsHilfe; and Strategic Advisor at the German Cancer Consortium (DKFZ). Prof. Eggermont was previously Director General of Gustave Roussy Comprehensive Cancer Center, Villejuif, France (2010-2019); and Professor of Surgical Oncology (2003-2016) and Endowed Professor of International Networking in Cancer Research (2011-2018) at Erasmus University MC, Rotterdam, the Netherlands. He holds a PhD in tumor immunology from Erasmus University and is Fellow of the National Institutes of Health’s National Cancer Institute (NIH-NCI). Prof. Eggermont has served as President of ECCO, President of the EORTC, was a member of the Board of Directors of ASCO, served on the Editorial Board of the Journal of Clinical Oncology, and is currently Editor-in-Chief of the European Journal of Cancer. Prof. Eggermont has published more than 900 peer-reviewed papers and his expertise has been acknowledged by many professional awards throughout his career (bio from Forbion.com).